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Abstract Various interaction modes between a group of
six ruthenium polypyridyl complexes and DNA have been
studied using a number of spectroscopic techniques. Five
mononuclear species were selected with formula [Ru(tpy)
L1L2]
(2-n)?, and one closely related dinuclear cation
of formula [{Ru(apy)(tpy)}2{l-H2N(CH2)6NH2}]
4?. The
ligand tpy is 2,20:60,200-terpyridine and the ligand L1 is a
bidentate ligand, namely, apy (2,20-azobispyridine), 2-
phenylazopyridine, or 2-phenylpyridinylmethylene amine.
The ligand L2 is a labile monodentate ligand, being Cl
-,
H2O, or CH3CN. All six species containing a labile L2 were
found to be able to coordinate to the DNA model base
9-ethylguanine by 1H NMR and mass spectrometry. The
dinuclear cationic species, which has no positions available
for coordination to a DNA base, was studied for comparison
purposes. The interactions between a selection of four
representative complexes and calf-thymus DNA were
studied by circular and linear dichroism. To explore a pos-
sible relation between DNA-binding ability and toxicity, all
compounds were screened for anticancer activity in a variety
of cancer cell lines, showing in some cases an activity which
is comparable to that of cisplatin. Comparison of the details
of the compound structures, their DNA binding, and their
toxicity allows the exploration of structure–activity rela-
tionships that might be used to guide optimization of the
activity of agents of this class of compounds.
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Abbreviations
apy 2,20-Azobispyridine
azpy 2-Phenylazopyridine
CD Circular dichrosim
ct-DNA Calf-thymus DNA
DMSO Dimethyl sulfoxide
9-EtGua 9-Ethylguanine
IC50 Concentration that induces 50% growth
inhibition of cells compared with untreated
cells
impy 2-Phenylpyridinylmethylene amine
LD Linear dichroism
MS Mass spectrometry
SAR Structure–activity relationship
tpy 2,20:60,200-Terpyridine
Introduction
Since the introduction of cisplatin in medical protocols
for treatment of certain cancers in 1978 [1], anticancer
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metallopharmaceuticals [2–4] have attracted significant
attention. The clinical drawbacks of cisplatin therapy soon
became apparent, including the limited applicability of the
medicine, the acquired resistance displayed by certain
tumors, and the serious side effects [5]. To design improved
antitumor platinum drugs, research has developed and
focused on understanding the mechanisms of the action of
cisplatin both in the living cell and in the body. To date,
DNA is generally accepted to be the main target of cisplatin,
which has been demonstrated to bind most frequently to two
adjacent guanine residues via their N7 position, thereby
generating a kink in the DNA structure [5, 6].
Initially anticancer research was guided by a few
structure–activity relationship (SAR) ‘‘rules’’ [7], which
dictated, for example, the structure that a platinum complex
should have for it to display anticancer activity, and
showed the importance of the lability of its ligands.
However, a number of compounds were reported later that
violated these rules, but that still displayed anticancer
activity [8–18]; it is now recognized that different molec-
ular-level drug actions are most readily achieved by
deliberately breaking the platinum drug SARs.
A relatively new line of investigation focuses on
ruthenium chemistry as an alternative metallopharma-
ceutical approach to platinum [19, 20]. The higher
coordination number of ruthenium compared with platinum
provides additional coordination sites, which can poten-
tially be used to fine-tune the properties of the complex, for
example, by influencing the way the complex interacts with
DNA [19]. The different redox properties of ruthenium can
also play an important role in the transport mechanisms of
the drug in the body, as well as in the interaction between
the drug and several different biologically relevant proteins
[19]. Other important factors are the differences in ligand
substitution kinetics and in the water solubility of the
compounds. Ruthenium chemistry may also allow for
photodynamic approaches to therapy [21–24].
Ruthenium anticancer chemistry has already yielded
many promising results. Several compounds have been
described which display an activity comparable to that
of cisplatin, and in some cases activities are even bet-
ter [25–30]. Indeed, two ruthenium dimethyl sulfoxide
(DMSO) compounds are currently in clinical trials [31, 32].
For one of these, NAMI-A, the compound does not show
dramatic cytotoxicity in tumor cell lines in vitro, but it
displays a very high activity against metastases [31, 32].
However, the mechanism of action of these compounds is
not well established and SARs are not yet known which
might provide starting points to optimize the design of any
ruthenium anticancer drug.
Nevertheless a large variety of potential ruthenium
drugs have been synthesized, with ligands such as amines,
imines, DMSO, polypyridyl compounds, and arenes [19,
33, 34]. The diversity of the active structures in fact sug-
gests that different mechanisms of action may be involved
for different types of ruthenium complex [35].
The present investigation focuses on ruthenium poly-
pyridyl coordination compounds which contain only one
available coordination site, in an attempt to see whether
this is a significant variable in ruthenium complex cyto-
toxicity. The selected series of ruthenium(II) complexes
contains the chelating polypyridyl ligand 2,20:60,200-
terpyridine (tpy), a bidentate arylazopyridine or arylimi-
nopyridine ligand, and also a labile monodentate ligand L2
[36–38] (Fig. 1). The choice of tpy as a coligand is based
on the known anticancer activity of some Ru(tpy)-
containing complexes [39, 40]. The bidentate ligand has
selected variations in the structure, for example, by
substituting a pyridine ring for a phenyl ring and an imino
group for an azo group. These variations, together with the
fact that three different labile ligands were used, would
hopefully allow for the proposal of a possible SAR.
For comparison reasons a symmetric, homodinuclear cat-
ionic species [{Ru(apy)(tpy)}2{l-H2N(CH2)6NH2}]
4? (1f),
where apy is 2,20-azobispyridine, was also synthesized
(Fig. 2), which, unlike complexes 1a, 1b, 1c, 1d, and 1e,
has no free positions available for coordination to a DNA
base. This compound might still interact with DNA through
a noncoordinative mechanism.
The DNA binding and cytotoxicity of these six new
agents were explored. These new complexes show a sig-
nificant cytotoxicity in several cell lines, and, equally
excitingly, the results obtained suggest that the mechanism
of action of this kind of ruthenium complex may be quite
different from that of the classic platinum anticancer agents.
Materials and methods
Starting reagents and coordination compounds
LiCl, NaClO4 (both from Merck), NaClO, AgNO3 (both
from Acros), tpy (Aldrich), RuCl33H2O (Johnson
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Fig. 1 Structure of [Ru(tpy)L1L2]
(2-n)? compounds (1a, 1b, 1c, 1d,
1e), where tpy is 2,20:60,200-terpyridine. The proton numbering scheme
for use in 1H NMR spectra is indicated as well
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Matthey), 9-ethylguanine (9-EtGua; Sigma), and H2N
(CH2)6NH2 (Fluka) were used as supplied. Ultrapure water
(18.2 MX; Aldrich) was used for the mass spectrometry
(MS), circular dichroism (CD), and linear dichroism (LD)
experiments. All other chemicals and solvents were reagent
grade, commercial materials and were used as received.
Calf-thymus DNA (ct-DNA) was purchased from
Sigma-Aldrich and used without further purification. The
solid DNA salt was dissolved in ultrapure water (18.2 MX;
Aldrich) and left at 278 K for 24 h to fully hydrate. The
resulting stock DNA solution was kept frozen and it was
thawed when needed. The concentration of the DNA stock
solution was determined spectroscopically, using the
known molar extinction coefficient of ct-DNA at 258 nm:
e258 = 6,600 molar base
-1 cm-1 dm3 [41].
A 100 mM stock solution of sodium cacodylate buffer
(pH 6.8) was prepared, as well as a 1 M sodium chloride
stock solution, using in both cases ultrapure water
(18.2 MX; Aldrich).
The ligands apy, 2-phenylazopyridine (azpy), and
2-phenylpyridinylmethylene amine (impy) and the metal
compounds Ru(tpy)Cl3, [Ru(apy)(tpy)Cl](ClO4), [Ru(apy)
(tpy)(H2O)](ClO4)22H2O, [Ru(apy)(tpy)(CH3CN)](ClO4)2,
[Ru(azpy)(tpy)Cl]Cl5H2O, and [Ru(impy)(tpy)Cl](ClO4)
were synthesized as described in the literature [42, 43] and
in our earlier reports [36–38].
Synthesis and characterization of [{Ru(apy)(tpy)}2
{l-H2N(CH2)6NH2}](ClO4)4
[Ru(apy)(tpy)(H2O)](ClO4)22H2O (26 mg, 0.034 mmol)
and H2N(CH2)6NH2 (2 mg, 0.016 mmol) were dissolved in
12 mL 5:1 absolute EtOH/MeOH. The solution was vigor-
ously refluxed for 15 h. The pH remained constant around 7.
The product was collected by filtration, washed with a little
ethanol and diethyl ether, and dried in vacuo over silica.
Yield: 20 mg (76%). Anal. calc. for C56H54N16O16Cl4Ru2:
C, 43.4; H, 3.5; N, 14.4%. Found: C, 43.8; H, 3.8; N, 14.5%.
m/z (electrospray ionization, ESI, MS) 634.1 ([Ru(apy)(tpy)
H2N(CH2)6NH2]
?); 576.1 ([Ru(apy)(tpy)]2[l-H2N(CH2)6
NH2]
2?); 317.3 ([Ru(apy)(tpy)] H2N(CH2)6NH2]
2?). 1H
NMR (DMSO-d6, 298 K): d (ppm) 9.34 (2H, d, 4.81 Hz);
9.00 (2H, d, 8.05 Hz); 8.62 (6H, m); 8.52 (2H, t, 6.84 Hz);
8.30 (4H, m); 8.14 (4H, t, 7.24 Hz); 7.78 (2H, d, 4.83 Hz);
7.73 (2H, t, 7.76 Hz); 7.46 (4H, t, 6.12 Hz); 7.30 (6H, m);
6.98 (2H, d, 7.98 Hz); 4.92 (4H, m); 1.64 (4H, m); 1.10
(4H, m); 0.66 (4H, m).
Physical measurements
Carbon, hydrogen, and nitrogen determinations were per-
formed with a PerkinElmer 2400 series II analyzer. Mass
spectra were obtained with a Finnigan AQA mass spec-
trometer equipped with an ESI source. NMR spectra were
recorded using a Bruker DPX-300 spectrometer operating
at a frequency of 300 MHz, at a temperature of 310 K,
unless otherwise stated. Chemical shifts were calibrated
against tetramethylsilane. CD spectra were collected in
2 mm path length quartz cuvettes using a JASCO J-810
spectropolarimeter. Flow LD spectra were collected using a
flow Couette cell in the abovementioned spectropolarime-
ter which has been adapted for LD spectroscopy. All CD
and LD spectra were recorded at room temperature.
In vitro cytotoxicity assays
Prior to the experiments, a mycoplasma test was carried out
on all cell lines and the test was negative. All cell lines
were maintained in a continuous logarithmic culture in
RPMI 1640 medium with 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonate and phenol red. The medium was
supplemented with 10% fetal calf serum, 100 U/mL peni-
cillin, and 100 lg/mL streptomycin. The cells were mildly
trypsinized for passage and for use in the experiments.
Cytotoxicity was estimated by the microculture sulforho-
damine B test [44].
A2780 (human ovarian carcinoma) and A2780R cis-
platin-resistant cell lines were maintained in continuous
logarithmic culture in Dulbecco’s modified Eagle’s med-
ium (Gibco BRLTM, Invitrogen, The Netherlands)
supplemented with 10% fetal calf serum (Perbio Science,
Belgium), 100 U/mL penicillin G sodium (Duchefa
Biochemie, The Netherlands), 100 lg/mL streptomycin
(Duchefa Biochemie, The Netherlands), and GlutaMAX
(1009; Gibco BRLTM, The Netherlands) in a humidified
5% CO2, 95% air atmosphere at 310 K. Cisplatin-sensitive
and cisplatin-resistant mouse leukemia L1210/0 and
L1210/2 cells were grown under the abovementioned
conditions. The cells were harvested from confluent mon-
olayers. Cell viability was determined by the trypan blue
dye exclusion test.
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Fig. 2 Structure of the dinuclear cation [{Ru(apy)(tpy)}2
{l-H2N(CH2)6NH2}]
4? (1f), where apy is 2,20-azobispyridine. The
proton numbering scheme for use in 1H NMR spectra is indicated as
well
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For the cytotoxicity evaluation in the cell lines WIDR,
IGROV, M19 MEL, A498, H226, MCF7, and EVSA-T, the
compounds were dissolved to a concentration of
250 lg/mL in full medium by 20-fold dilution of a stock
solution which contained 1 mg of compound per 200 lL
DMSO. Trypsinized tumor cells (about 150 lL, 1,500–
2,000 cells per well) were plated in 96-well flat-bottomed
microtiter plates (Falcon 3072, BD). The plates were pre-
incubated for 48 h at 310 K, 5.5% CO2. A threefold
dilution sequence of ten steps was then made in full
medium, starting with the 250.000 lg/mL stock solution.
Every dilution was used in quadruplicate by adding 50 lL
to a column of four wells, resulting in a highest concen-
tration of 62.500 mg/mL. The plates were incubated for
5 days, after which the cells were fixed with 10% trichlo-
roacetic acid in phosphate-buffered saline and placed at
277 K for 1 h. After three washings with water, the cells
were stained for at least 15 min with 0.4% sulforhodamine
B dissolved in 1% acetic acid. The cells were washed with
1% acetic acid to remove the unbound stain. The plates
were air-dried and the bound stain was dissolved in 150 lL
of 10 mM tris(hydroxymethyl)aminomethane. The absor-
bance was read at 540 nm using an automated microplate
reader (Labsystems Multiskan MS). Data were used for
construction of concentration–response curves and deter-
mination of the concentration that induces 50% growth
inhibition of cells compared with untreated cells (IC50) by
use of the Deltasoft 3 software program.
In the case of cell lines A2780, A2780R, L1210/0, and
L1210/2, 2,000 cells per well were seeded in 150 lL of
complete medium in 96-multiwell flat-bottomed microtiter
plates (Corning Costar). The plates were incubated at
310 K, 5% CO2 for 48 h prior to drug testing to allow cell
adhesion. The stock solutions of all compounds tested were
freshly prepared and directly used for the dilutions. Both 1a
and a-[Ru(azpy)2Cl2] are poorly water soluble, so for the
sake of comparison with the water-soluble compounds, a
DMSO/H2O stock solution was chosen for all the com-
pounds tested, except compound 1f. The latter was
dissolved directly in water, to avoid decomposition. The
nondecomposition was proved by the CD and LD experi-
ment. The dilutions (eight-step dilutions) were prepared in
complete medium. The final tested concentrations were
0.019, 0.012, 0.0015, 0.0009, 0.0005, 0.0001, 0.00005, and
0.00001 mM in the case of a-[Ru(azpy)2Cl2] and 0.17,
0.11, 0.06, 0.04, 0.01, 0.003, 0.001, and 0.0003 mM for the
other compounds. Each concentration was tested in qua-
druplicate, using 45 lL per well added to the 150 lL of
complete medium. In the control group only 45 lL of
complete medium was added containing the corresponding
percentages of H2O and DMSO. The maximum content of
DMSO in the wells was 0.96%. Parallel experiments
showed that no difference in cell proliferation was
observed in control groups with or without 1% DMSO. The
plates were incubated for 48 h and the evaluation of cell
proliferation was performed by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide colorimetric
assay [45–47]. About 50 lL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide solution (5 mg/mL
in phosphate-buffered saline, Sigma Chemical) was added
to each well and incubated for 3 h. Formazan crystals were
dissolved in 100 lL DMSO. Optical density was measured
using a microplate reader (Bio-Rad) at 590 nm. IC50 values
were obtained by GraphPad Prism, version 3.02.
Interaction between ruthenium polypyridyl complexes
and 9-ethylguanine
Aqueous solutions with a 1.3 mM concentration of the
ruthenium compound and a 2.6 mM concentration of the
DNA model base 9-EtGua were incubated at 310 K for
24 h. Subsequently the mass spectrum of each of the
mixtures was recorded. m/z (ESI-MS) of the mixture
1a ? 9-EtGua: 618.1 [Ru(apy)(tpy)](ClO4)
?; 554.2
([Ru(apy)(tpy)Cl]?); 536.3 ([Ru(apy)(tpy)(H2O)]
?); 348.9
([Ru(apy)(tpy)(9-EtGua)]2?). m/z (ESI-MS) of the mixture
1b ? 9-EtGua: 696.7 ([Ru(apy)(tpy)(9-EtGua)]?); 617.6
[Ru(apy)(tpy)](ClO4)
?; 535.7 ([Ru(apy)(tpy)(H2O)]
?);
517.7 ([Ru(apy)(tpy)]?); 348.9 ([Ru(apy)(tpy)(9-EtGua)]2?).
m/z (ESI-MS) of the mixture 1d ? 9-EtGua: 695.8
([Ru(azpy)(tpy)(9-EtGua)]?); 552.7 ([Ru(azpy)(tpy)Cl)]?);
534.8 ([Ru(azpy)(tpy)(H2O)]
?); 348.3 ([Ru(azpy)(tpy)
(9-EtGua)]2?). m/z (ESI-MS) of the mixture 1e ? 9-Et-
Gua: 695 ([Ru(impy)(tpy)(9-EtGua)]?); 616 [Ru(impy)
(tpy)](ClO4)
?; 552 ([Ru(impy)(tpy)Cl]?); 534 ([Ru(impy)
(tpy)(H2O)]
?); 516 ([Ru(impy)(tpy)]?); 348 ([Ru(impy)(tpy)
(9-EtGua)]2?).
Each ruthenium compound was dissolved in 600 lL
D2O and the appropriate amount of 9-EtGua was added to
prepare solutions with a 1.3 mM concentration of the
ruthenium compound and 2.6 mM 9-EtGua. The interac-
tion between each ruthenium complex, H2O, and 9-EtGua
was followed by 1H NMR for 24 h at 310 K.
Interaction between ruthenium polypyridyl complexes
and calf-thymus DNA
Fresh samples were made with constant concentrations of
DNA (300 lM in ultrapure water for the experiments
involving complexes 1b, 1d, and 1e and 100 lM concen-
tration for the experiment with complex 1f), NaCl
(20 mM), and sodium cacodylate buffer (1 mM), and a
range of the metal concentration using a concentrated stock
solution of each complex (500 lM 1b, 1d, and 1e and
300 lM 1f in in ultrapure water). The ratio of DNA to
metal complex was decreased from 50:1 to 1.5:1 in the
442 J Biol Inorg Chem (2009) 14:439–448
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various samples. The CD spectra of these solutions were
measured after 24 h of incubation at 310 K. The solutions
prepared with complex 1f were also measured fresh.
For the LD measurements, a 300 lM solution of DNA
in ultrapure water containing NaCl (20 mM) and sodium
cacodylate buffer (1 mM) was prepared. This solution was
titrated with two stock solutions. The first solution con-
tained each of the complexes 1b, 1d, and 1e in 1,000 lM
concentration in ultrapure water or complex 1f in 500 lM
concentration. The second stock solution contained DNA
(600 lM), NaCl (40 mM), and sodium cacodylate buffer
(2 mM). The DNA, NaCl, and sodium cacodylate con-
centrations were kept constant, while the ratio of DNA to
metal complex was decreased from 20:1 to 3:1 for com-
plexes 1b, 1d, and 1e and from 40:1 to 6:1 for complex 1f.
Results and discussion
Synthesis and characterization of the coordination
compounds
The anticancer activity of compounds analogous to 1a, 1b,
1c, 1d, and 1e is easily hypothesized to be related to their
ability to bind to DNA model bases. To prove this relation
and eliminate other possible mechanisms of action of the
ruthenium complexes, the compounds in Fig. 1 and an
additional new compound 1f (Fig. 2) were synthesized.
The design and choice of 1f was based on the following
arguments. Its inability to bind to DNA by metal coordi-
nation, due to the blockage of the six coordination
positions of ruthenium by nonlabile ligands, would allow
the DNA-binding–cytotoxicity relationship to be proved.
On the other hand, the compound was chosen to be sym-
metrical and analogous to the mononuclear parent
compounds 1a, 1b, and 1c to make the comparison
amongst all these complexes as valid as possible. Finally a
chain was added that was long enough to allow complex 1f
to act as two units of the parent compound.
Compound 1f was found to be pure by 1H NMR and
elemental analysis and was characterized by ESI-MS. The
mass spectrum showed a peak corresponding to the dinu-
clear species and also peaks corresponding to the
mononuclear fragment arising from fragmentation under
the conditions used. The 1H NMR spectrum of 1f was
recorded in DMSO-d6 because although the solubility of
this compound in water was adequate for cell testing, it was
not sufficient for 1H NMR. Full spectral assignment was
made using correlation spectroscopy and nuclear Overha-
user effect spectroscopy experiments (Table 1). The
stability of 1f in water was studied by dissolving it in
water, incubating the solution at 310 K for 2 weeks,
evaporating the water, and subsequently recording the 1H
NMR spectrum in DMSO-d6. The compound was found to
remain unchanged after this time.
In vitro cytotoxicity assays
The cytotoxicity of compounds 1a, 1b, 1c, 1d, 1e, and 1f
was tested in vitro in a series of selected cell lines
belonging to the currently used anticancer screening panel
of the National Cancer Institute, USA [48]: WIDR (human
colon cancer), IGROV (human ovarian cancer), M19 MEL
(human melanoma), A498 (human renal cancer), and H226
(non-small human cell lung cancer). The human breast
cancer cell lines MCF7 and EVSA-T [estrogen receptor
(ER)?/progesterone receptor (PgR)? and (ER)-/(PgR)-,
respectively] were also included as were the cisplatin-
sensitive and cisplatin-resistant mouse leukemia L1210/0
and L1210/2 cells and A2780 (human ovarian carcinoma)
and A2780R cisplatin-resistant cell lines.
The cytotoxicity of the mononuclear [Ru(apy)(tpy)
L2
n-](2-n)? complexes (1a, 1b, 1c) and that of their dinu-
clear analogue [Ru(apy)(tpy)]2[l-H2N(CH2)6NH2](ClO4)4
(1f) against several selected cell lines were compared to see
the differences that might arise from their structural dif-
ferences. All compounds showed good activity in the
EVSA-T cell line and moderate activity in H226, M19
MEL and MCF7 cell lines (Table 2), suggesting the dif-
ferent axial ligands have little effect on their activity.
A minor difference was also noted between these com-
pounds in A2780 normal and resistant cell lines and the
L1210 cells lines, though the compounds were generally
found to be ineffective in the latter.
The non-azo complex 1e showed very low or no activity
at all in the cell lines tested (Table 3), indicating that the
azo group is important for activity. The most active drug in
the case of the nonresistant cell line, A2780, was found to
be 1b, but all the drugs were significantly less active than
cisplatin, whereas in the resistant cell lines all the activities
Table 1 Proton chemical shift values (given in parts per million) for [{Ru(apy)(tpy)}2{l-H2N(CH2)6NH2}](ClO4)4 (1f), where apy is 2,20-
azobispyridine and tpy is 2,20:60,200-terpyridine, recorded in dimethyl sulfoxide-d6 at 298 K
6A 3A 3T 3T0 4A 5A 4T0 4T 6A0 4A0 5T 5A0 6T 3A0 NH2 (CH2)a (CH2)b (CH2)c
9.34 9.00 8.62 8.52 8.30 8.14 7.78 7.73 7.46 7.30 6.98 4.92 1.64 1.10 0.66
The proton labeling as given in Fig. 2 has been used. The assignment of the proton signals was based on 2D NMR spectra (data not shown,
assignments based on [36])
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are comparable to that of cisplatin and similar to that of the
nonresistant cell line, suggesting a mechanism of action
different from that of cisplatin. In the case of the murine
leukemia cell lines L1210 1b was found by way of contrast
one of the least effective compounds, and 1a, 1c, and 1d
show somewhat better activity in the resistant cell line than
in the nonresistant one. Neither the non-azo complex (1e)
nor the homodinuclear complex (1f) shows any activity in
the L1210 cell lines.
Interaction between ruthenium polypyridyl complexes
and 9-ethylguanine
It is generally accepted that the target for cisplatin is DNA,
as discussed earlier. The compounds of this study were also
designed to target DNA. However, it is clear from the
cytotoxicity studies that the resistance mechanisms devel-
oped for cisplatin do not affect the compounds of this work.
The first question was whether they could coordinatively
bind to guanine by displacement of the labile ligand. In this
respect it should be mentioned that a previous 1H NMR
study of the interaction between each of the complexes 1a,
1b, and 1c ([Ru(apy)(tpy)L2]
(2-n)?, where L is Cl-, H2O,
and CH3CN, respectively) and 9-EtGua [49] demonstrated
that these three complexes are capable of binding to the
DNA model base in water at 310 K and pH 7, albeit with
different kinetics in each case. We therefore carried out an
analogous study involving 9-EtGua and the new cationic
complexes [Ru(azpy)(tpy)Cl]? (1d) and [Ru(impy)(tpy)
Cl]? (1e), respectively. The hydrolysis of these complexes
in the absence of the DNA model base was also investi-
gated by 1H NMR under the same experimental conditions.
Comparison of the spectra (data shown in the electronic
supplementary information) indicated that both compounds
1d and 1e undergo two reactions, similar to the previously
reported ones for 1c [49], i.e., hydrolysis followed by the
formation of a ruthenium–base adduct. The reaction
between 1d and 9-EtGua is estimated to reach its maximum
in about 2 h, with an approximate conversion of 25%,
while complex 1e yields as much as a 60% conversion after
9 h (Fig. S1, Table S1). The maximum conversions
observed in the cases of complexes 1b and 1c were
reported to be 20% in 5 h and 30% in 18 h, respectively
[49]. ESI-MS confirmed the 9-EtGua binding for each of
the chlorido complexes 1a, 1d, and 1e after incubation for
24 h at 310 K. The spectrum of 1a and 9-EtGua showed a
peak at m/z 348.9, corresponding to the species [Ru(apy)
(tpy)(9-EtGua)]2?. Two peaks appeared in the spectrum of
Table 2 Concentration that induces 50% growth inhibition of cells compared with untreated cells (IC50) (lM) of the [Ru(apy)(tpy)L2
n-](2-n)?
complexes (1a, 1b, 1c) and their dinuclear analogue [Ru(apy)(tpy)]2[l-H2N(CH2)6NH2](ClO4)4 (1f) after a 5-day treatment with selected cell
lines
Compound tested A498 EVSA-T H226 IGROV M19 MEL MCF7 WIDR
[Ru(apy)(tpy)Cl](ClO4) (1a) [96 7 17 [96 25 13 66
[Ru(apy)(tpy)(H2O)](ClO4)22H2O (1b) [81 6 17 44 26 18 50
[Ru(apy)(tpy)(CH3CN)] (ClO4)2 (1c) [82 6 26 78 30 21 73
[Ru(azpy)(tpy)Cl]Cl5H2O (1d) 39 11 34 65 15 30 51
[Ru(apy)(tpy)]2[l-H2 N(CH2)6NH2] (ClO4)4 (1f) [40 17 28 [40 33 [40 [40
a-[Ru(azpy)2Cl2] 0.3 0.1 0.5 0.3 0.1 0.3 0.3
Cisplatin 2 1 2 0.2 3 2 2
a-[Ru(azpy)2Cl2] and cisplatin have been included as reference compounds
Table 3 IC50 values (lM) of the [Ru(tpy)L1L2
n-](2-n)? complexes (1a, 1b, 1c, 1d, 1e) and the dinuclear complex [Ru(apy)(tpy)]2[l-
H2N(CH2)6NH2](ClO4)4 (1f) after a 48-h treatment in some selected cell lines
Compound tested A2780 A2780R L1210/0 L1210/2
[Ru(apy)(tpy)Cl](ClO4) (1a) 23 25 100 56
[Ru(apy)(tpy)(H2O)](ClO4)22H2O (1b) 11 30 80 97
[Ru(apy)(tpy)(CH3CN)] (ClO4)2 (1c) 31 28 70 40
[Ru(azpy)(tpy)Cl]Cl5H2O (1d) 19 42 42 26
[Ru(impy)(tpy)Cl] (ClO4) (1e) [100 62 [100 [100
[Ru(apy)(tpy)]2[l-H2N(CH2)6NH2] (ClO4)4 (1f) 33 28 [100 [100
a-[Ru(azpy)2Cl2] 0.1 0.2 0.1 0.2
Cisplatin 6 25 2 24
a-[Ru(azpy)2Cl2] and cisplatin have been included as reference compounds
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1d ? 9-EtGua at m/z 695.8 and 348.3, corresponding to the
species [Ru(azpy)(tpy)(9-EtGua)]? and [Ru(azpy)(tpy)
(9-EtGua)]2?, respectively. The mass spectrum of 1e ?
9-EtGua similarly showed two peaks at m/z 695 ([Ru(impy)
(tpy)(9-EtGua)]?) and 348 ([Ru(impy)(tpy)(9-EtGua)]2?).
Peaks corresponding to hydrolysis products were also
observed for each complex.
Interaction between ruthenium polypyridyl complexes
and calf-thymus DNA
That coordination binding of the compounds to guanine is
possible does not necessarily imply that such binding can
also happen in the more constrained environment of duplex
DNA. The addition of the metal complexes to ct-DNA
resulted in small changes in the UV–vis absorption spectra.
This behavior is not necessarily indicative of a noncovalent
interaction, since previous reports on [Ru(bpy)(tpy)X]n?
systems, where bpy is 2,20-bipyridine, showed that
replacement of the chloride by an aqua ligand, or by a
guanine DNA base, leads to only very small changes in the
metal-to-ligand charge transfer spectra [50, 51].
To probe the binding of the complexes to polymeric
ct-DNA in more detail we also recorded CD spectra. CD is a
well-established analytical tool for the study of conforma-
tional changes in chiral systems [52, 53] and has often been
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Fig. 3 Top circular dichroism (CD) spectra of 300 lM calf-thymus
DNA (ct-DNA) incubated for 24 h with increasing concentrations of
the mononuclear ruthenium complexes 1b (left), 1d (center), and 1e
(right). The DNA base pairs to ruthenium complex molecules ratios
are 20:1, 10:1, 5:1, 3:1, 2.5:1, 2:1, and 1.5:1. Bottom CD spectra of
100 lM ct-DNA with increasing concentrations of the dinuclear
complex 1f, from freshly prepared samples (left) and from samples
incubated for 24 h (right). The DNA base pairs to ruthenium complex
molecules ratios are 50:1, 10:1, 5:1, 3.5:1, 2.5:1, and 2:1; the last two
ratios were eliminated in the incubated sample, because of precip-
itation. The solid line represents the ct-DNA; some of the curves are
labeled with the base pairs to ruthenium complex molecules ratios.
The bold arrows indicate an increase in ruthenium concentration
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used for the study of DNA–metal complex systems [54–58],
including ruthenium metallodrug complexes [30, 59–63]
where an induced CD signal is indicative of binding to the
chiral DNA. The ruthenium complexes 1b, 1d, 1e, and 1f
were therefore mixed with ct-DNA in a range of ratios and
left to incubate for 24 h at 310 K. Complex 1b is the aqua
analogue of complex 1a, and was used for this study
because of its much higher water solubility. The CD spectra
of these samples after incubation are shown in Fig. 3. The
DNA region of the spectrum shown from 220 to 300 nm is
characteristic of retention of a B-DNA conformation,
whereas the induction of a positive CD signal at approxi-
mately 330 nm when 1e is incubated with ct-DNA shows it
binds strongly. This transition is associated with the pyr-
idylimine unit [38]; a similar CD band is not observed for
the azopyridine-containing complexes. Nevertheless,
changes in the DNA region of the spectrum are indicative of
interactions between the DNA and these other compounds.
While the B-DNA conformation is clearly retained,
small changes in the bands in the DNA region of the
spectrum are difficult to interpret, as induced CD signals
from the ligand-based spectroscopic transitions of the
compounds also fall in this region. In fact for 1b and 1e the
changes are similar to those reported for the ruthenium(II)
compound [(g6-p-cymene)Ru(en)(Cl)]?, where en is ethy-
lenediamine [64]. The solutions were prepared and allowed
to stand for 24 h, to obtain full hydrolysis. Solutions with
complex 1f were also measured fresh for comparison.
Compound 1f is a tetracation and therefore DNA pre-
cipitation was observed at high loading. In this case the B-
DNA conformation is also clearly retained.
Flow LD (defined as the difference in absorption of light
polarized parallel and perpendicular to an orientation axis
[52, 65] when the sample is subject to flow) is also sensi-
tive to interactions between DNA and ligands. In this study
we used a Couette cell, in which one cylinder rotates inside
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Fig. 4 Linear dichroism spectra of 300 lM ct-DNA with increasing
concentrations of the ruthenium complexes 1b (top left), 1d (bottom
left), 1e (top right), and 1f (bottom right). The DNA base pairs to
ruthenium complex molecules ratios are 20:1, 15:1, 10:1, 8:1, 5:1,
3.5:1, 3:1, 2.5:1, and 2:1 in the case of the mononuclear complexes
(1b, 1d and 1e) and 40:1, 20:1, 15:1, 10:1, 8:1, and 6:1 for the
dinuclear complex (1f). The solid line represents the ct-DNA. The
arrows indicate the direction of an increase in ruthenium
concentration
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another, with the sample in the gap between the cylinders
[66]. Since the base pairs are oriented perpendicular to the
DNA helix axis, a negative LD signal is expected for B-
DNA (Fig. 4, band at 258 nm). The LD signal of bound
metal complexes indicates the orientations they adopt on
the DNA [64, 67–69]. In addition, LD is a useful tool for
assessing DNA coiling [58, 65, 70, 71]. When reacted with
DNA, 1b, 1d, and 1f show a positive LD signal at 330 nm
(whereas 1e shows none), confirming the specific binding
of these complexes to DNA. The absence of the band in 1e
could simply reflect different polarization of transitions in
the pyridylimine and azopyridine complexes. This means
the azopyridine ligand based transition [38] lies more
parallel than perpendicular to the DNA helix axis.
For each complex the DNA LD signal at 258 nm
decreases in magnitude upon addition of the ruthenium
complex, though the effect is small compared with that
induced by the metallocylinders that have been reported to
coil DNA [58, 65].
Concluding remarks
The IC50 values found for the apy complexes 1a, 1b, and
1c suggest no correlations exist between the lability of the
axial leaving group and the cytotoxicity of the compound.
From the results with 9-EtGua binding, the most rapidly
reacting is the azpy complex 1d, the slowest reacting is 1c,
whereas the impy complex 1e yields the maximal con-
version. From the IC50 values for 1c, 1d, and 1e it is
evident that, the ability of the compounds to bind to 9-
EtGua and their anticancer activity are uncorrelated. The
mechanisms of activity of the dinuclear coordinatively
saturated compound 1f must be different from the mech-
anisms of other compounds, as it cannot bind to a DNA
base; however, its cytotoxic activity is comparable to that
of the mononuclear compounds. A small effect on the
DNA band in LD is observed with non-covalent-binding
dinuclear complex 1f that may indicate some DNA
bending or coiling, The effect is small compared with the
dramatic effects caused by the non-coordinative-binding
dinuclear cylinder compounds which can interact in the
major groove of DNA [65, 70, 71], as well as in three-way
junctions [72, 73].
In conclusion, a set of ruthenium compounds with dif-
fering axial ligands and internal functional groups was
synthesized. The cytotoxicity of the compounds appears to
be unaffected by the nature of axial ligand leaving group
and the dinuclear compound which lacks a leaving group
shows activity similar to that of the other compounds.
Nevertheless, the presence of the azo group is required
for anticancer activity. Interestingly [Ru(bpy)(tpy)Cl]Cl,
which is to some extent analogous to the compounds
described herein, and which also lacks an azo group, has
also been reported to be inactive [40]. In general, the
activity of compounds is not affected by the cisplatin
resistance mechanisms, suggesting their modes of action
differ. Their efficacy is in some cases better than that of
cisplatin in resistant cells. The mononuclear compounds
can all bind to the isolated model base 9-EtGua, but their
DNA binding neither results in kinking like with cisplatin
nor in the coiling as known for the dimetallo helicates [65].
At this stage we cannot exclude the possibility that the
target of these compounds is DNA, since they all bind to
DNA in a non-cisplatin mode.
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